Autolus Therapeutics plc

FDA’s Marks says risk of secondary cancers from CAR Ts smaller than feared

Plus: BridgeBio’s Attruby approved for ATTR-CM, PTC’s gene therapy for AADC deficiency, and Gilead withdrew Trodelvy for urothelial cancer

Company’s first goals are to improve GLP-1s and CAR Ts with the ability to go from zero to very high expression, on demand

Upcoming decisions include BridgeBio’s 

Plus: Autolus hires Matthias Will as CDO, and updates from HotSpot, Prilenia, Frazier, BIA and BioCentriq

Plus: Bodmer to lead Nucleome as CEO and updates from Nouscom, Oxford Biomedica and Aslan

Plus: Audrey Duval to lead corporate affairs at Sanofi, and updates from MOMA,

Plus: LianBio begins winding down, promises dividend; BioXcel pulls offering

Off switches and non-viral delivery technologies may be the solution to CAR Ts’ most recent safety problem

BioCentury’s weekly roundup of biopharma deals